Indianapolis-based drugmaker Eli Lilly and Company has announced price ... Additionally, Lilly is launching Rezvoglar (insulin glargine-aglr) injection, a basal insulin that is biosimilar to ...

Eli Lilly’s big-selling insulin ... acting insulin market with a cheaper version of Sanofi’s Lantus (insulin glargine). Approved at the beginning of 2016, US revenues of the cheaper competitor ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...

On Wednesday, pharmaceutical giant Eli Lilly sued four prominent telehealth companies that offer more affordable, off-brand versions of its patented best-selling GLP-1 medications Mounjaro and ...